Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP Inhibitors
- 1 June 2001
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (12) , 1553-1556
- https://doi.org/10.1016/s0960-894x(01)00031-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770Bioorganic & Medicinal Chemistry Letters, 2001
- N -Formyl hydroxylamine containing dipeptides: generation of a new class of vasopeptidase inhibitorsBioorganic & Medicinal Chemistry Letters, 2000
- Chapter 15. Matrix metalloproteinase inhibitors for treatment of cancerPublished by Elsevier ,2000
- Recent Advances in Matrix Metalloproteinase Inhibitors ResearchCurrent Pharmaceutical Design, 1999
- Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.Journal of Clinical Oncology, 1998
- Broad spectrum matrix metalloproteinase inhibitors: An examination of succinamide hydroxamate inhibitors with P1 Cα gem-disubstitutionBioorganic & Medicinal Chemistry Letters, 1998
- Matrix Metalloproteinase Inhibitors and CancerPublished by Elsevier ,1998
- Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMRJournal of the American Chemical Society, 1997
- Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase InhibitorsCurrent Pharmaceutical Design, 1997